Stellaromics Inc.
Mark Pratt is an accomplished engineering fellow at Stellaromics Inc., focusing on the advancement of spatial 'omics technologies. As a co-founder and CTO at Ultima Genomics, Mark played a pivotal role in pioneering cost-effective DNA sequencing, achieving a remarkable price point of $100 per human genome. With extensive experience as a principal at Voyager Technologies, Mark offers expertise in system engineering, informatics, and product development. Previous positions include senior director of accuracy R&D at Personalis, where Mark was instrumental in creating innovative assays for DNA sequencing, and principal engineer roles at Illumina and Solexa, where Mark contributed to the development of market-leading sequencing systems. Academic qualifications include a PhD in Physics from the University of California, Santa Barbara, as well as additional degrees and postdoctoral research from UC San Diego, MIT, the University of Washington, and Walla Walla University.
This person is not in the org chart
This person is not in any teams
Stellaromics Inc.
Founded in 2022 and headquartered in Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations. Stellaromics is currently in the advanced stages of developing its Plexa™ suite of products, meticulously crafted to empower researchers and clinicians in the creation of intricate cellular maps, thereby amplifying our comprehension of various diseases. For comprehensive details, we invite you to explore our website at stellaromics.com. Join us in shaping the future of biomedical research.